Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes

Table 2 Associations between patient characteristics and time to remission and relapse by Cox-regression analysis

Characteristic	Remission		Relapse
Characteristic	HR (95% CI)	P	HR (95% CI)	P
Age (years)^a	0.97 (0.83–1.12)	0.64	0.81 (0.64–1.01)	0.06
Gender		0.62		0.32
Male	1		1
Female	0.86 (0.49–1.54)		1.46 (0.70–3.03)
Ethnicity		0.75		0.93
White	1		1
South Asian	0.60 (0.21–1.74)		1.01(0.30–3.38)
Black	0.72 (0.27–1.91)		0.61 (0.14–2.57)
Other	0.72 (0.10–5.32)		N/A
Serum creatinine (μmol/L)^b	0.99 (0.95–1.03)	0.72	0.97 (0.90–1.03)	0.30
Estimated GFR (mL/min/1.73m²)^a	1.00 (0.91–1.09)	0.98	1.18 (1.03–1.36)	0.016
Baseline AKI	1.12 (0.61–2.05)	0.71	0.71 (0.33–1.53)	0.38
Proteinuria
ACR (mg/mmol)^c	1.04 (0.93–1.17)	0.51	1.06 (0.94–1.20)	0.34
24 h collection (g/24 h)^d	1.25 (0.99–1.59)	0.06	1.01 (0.84–1.21)	0.92
Serum albumin (g/L)^e	0.88 (0.69–1.13)	0.32	1.10 (0.83–1.46)	0.50
Serum cholesterol (mmol/L)^d	1.02 (0.95–1.11)	0.53	1.02 (0.92–1.14)	0.65
Haematuria	0.79 (0.24–2.62)	0.70	0.33 (0.04–2.47)	0.28
Steroid resistance			1.45 (0.44–4.80)	0.54
Time to remission (weeks)^d			0.99 (0.96–1.02)	0.68
Duration of initial course of prednisolone^f			0.88 (0.72–1.06)	0.18

HR hazard ratio; CI confidence interval; GFR glomerular filtration rate; AKI acute kidney injury; ACR albumin-to-creatinine ratio. ^aper 10 units; ^bper 20 units; ^cper 100 units; ^dper 1 unit; ^eper 5 units; ^fper 1 month of therapy, analysed after excluding those who relapsed while still on their initial prednisolone

ISSN: 1471-2369